Finally, our observations confirm high usability and good appreciation of VitaPCR™ platform for its short duration of analysis (20 min), the little place occupied, and the possibility of point‐of‐care use, although only a single sample analysis is considered as a limiting factor. Furthermore, the analytical performances of the VitaPCR™ platform were high and close to those of reference rRTPCR in the event of significant viral load. In conclusion, the VitaPCR™ SARS‐CoV‐2 Assay is an accurate rapid point‐of‐care NAAT, suitable for clinical practice for the rapid diagnosis of COVID‐19, especially in patients with COVID‐19‐suspected symptoms.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250980
